The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2020Target Validation Studies for the Discovery of Novel Small Molecule Therapeutics with the Potential to Modify Disease Outcome by Inhibiting Bacterial Amyloid Protein-induced Alpha-synuclein Aggregation and Associated Neuronal Toxicity
Study Rationale:
Patients with Parkinson’s disease frequently report serious gastrointestinal (GI) symptoms, most commonly constipation, which are not well treated with currently available medicine... -
Improved Biomarkers and Clinical Outcome Measures, 2020RT-QuIC Testing of Misfolded Alpha-synuclein in S4 Study Samples
Study Rationale:
The protein alpha-synuclein is vital to normal brain function. In Parkinson's disease, alpha-synuclein misfolds, forming aggregates, or clumps, that impair the ability of brain cells... -
Improved Biomarkers and Clinical Outcome Measures, 2020Quantification of S129 Phosphorylated Alpha-Synuclein Using the AlphaLISA Immunoassay Platform
Study Rationale:
In Parkinson's, there remains an unmet need for biomarkers to track disease progression and efficacy of potential therapies. This team of investigators is focused on fluid-based... -
Access to Data and Biospecimens, 2020Development of a Biomarker Platform for Parkinson’s Disease Using Patient-derived Cells
Study Rationale:
Inadequate understanding of how Parkinson's disease develops is a major roadblock in developing effective therapeutics and methods to diagnose the disease earlier. This project... -
Improved Biomarkers and Clinical Outcome Measures, 2020PPMI DATIQ and SR T1w MRI Analysis
Study Rationale:
Parkinson’s disease results in functional and structural changes in the brain. Non-invasive imaging methods such as SPECT and MRI can measure these changes. The dopamine transporter... -
Improved Biomarkers and Clinical Outcome Measures, 2020Predicting Conversion to Parkinson’s Disease Based on Proteomic Biomarkers in a Large Prospective Cohort
Study Rationale:
The ultimate aim in Parkinson’s disease research is to identify individuals at risk for developing Parkinson’s prior to disease onset. To reach this goal, a set of informative markers...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.